Charles S Berenson1, Mary Alice Garlipp, Lori J Grove, Jane Maloney, Sanjay Sethi. 1. Division of Infectious Diseases, Department of Veterans Affairs Western New York Healthcare System, State University of New York at Buffalo School of Medicine, Buffalo, NY 14215, USA. berenson@acsu.buffalo.edu
Abstract
BACKGROUND: Interactions of nontypeable Haemophilus influenzae (NTHI) with human alveolar macrophages are implicated in the persistence of NTHI in chronic obstructive pulmonary disease (COPD). However, the immunologic mechanisms that mediate NTHI-induced macrophage responses are poorly understood. We hypothesized that immunologic responses of alveolar macrophages to NTHI are impaired in COPD. METHODS: Blood and alveolar macrophages--obtained from ex-smokers with COPD (n = 14), ex-smokers without COPD (n = 15), and nonsmokers (n = 9)--were incubated with 3 distinct NTHI strains obtained from patients with COPD. Phagocytosis of 3H-NTHI, expressed as a percentage of the mean total radioactivity, and of intracellular viability, assessed as a percentage of viable cell-associated NTHI, were measured. RESULTS: Alveolar macrophages from donors with COPD, compared with those from donors without COPD, had impaired phagocytosis (median [interquartile range]) for each NTHI strain: 14P13H5, 0.26 (0.08-0.61) versus 1.36 (0.69-1.95); 6P5H1, 0.92 (0.32-1.82) versus 1.90 (1.32-2.68); and 14P14H1, 0.79 (0.23-1.32) versus 2.13 (1.13-2.40) (P < or = .01 for each). However, phagocytosis of all NTHI strains by blood macrophages from donors with COPD was indistinguishable from that of blood macrophages from donors without COPD and from nonsmokers. The intracellular killing of NTHI was not impaired in alveolar macrophages from donors with COPD. CONCLUSIONS: These results support a paradigm of impaired phagocytosis by alveolar macrophages, but not blood macrophages, in COPD and provide an immunologic basis for persistence of NTHI in the airways of adults with COPD.
BACKGROUND: Interactions of nontypeable Haemophilus influenzae (NTHI) with human alveolar macrophages are implicated in the persistence of NTHI in chronic obstructive pulmonary disease (COPD). However, the immunologic mechanisms that mediate NTHI-induced macrophage responses are poorly understood. We hypothesized that immunologic responses of alveolar macrophages to NTHI are impaired in COPD. METHODS: Blood and alveolar macrophages--obtained from ex-smokers with COPD (n = 14), ex-smokers without COPD (n = 15), and nonsmokers (n = 9)--were incubated with 3 distinct NTHI strains obtained from patients with COPD. Phagocytosis of 3H-NTHI, expressed as a percentage of the mean total radioactivity, and of intracellular viability, assessed as a percentage of viable cell-associated NTHI, were measured. RESULTS: Alveolar macrophages from donors with COPD, compared with those from donors without COPD, had impaired phagocytosis (median [interquartile range]) for each NTHI strain: 14P13H5, 0.26 (0.08-0.61) versus 1.36 (0.69-1.95); 6P5H1, 0.92 (0.32-1.82) versus 1.90 (1.32-2.68); and 14P14H1, 0.79 (0.23-1.32) versus 2.13 (1.13-2.40) (P < or = .01 for each). However, phagocytosis of all NTHI strains by blood macrophages from donors with COPD was indistinguishable from that of blood macrophages from donors without COPD and from nonsmokers. The intracellular killing of NTHI was not impaired in alveolar macrophages from donors with COPD. CONCLUSIONS: These results support a paradigm of impaired phagocytosis by alveolar macrophages, but not blood macrophages, in COPD and provide an immunologic basis for persistence of NTHI in the airways of adults with COPD.
Authors: Shyamala Ganesan; Andrea N Faris; Adam T Comstock; Joanne Sonstein; Jeffrey L Curtis; Uma S Sajjan Journal: Am J Pathol Date: 2011-11-08 Impact factor: 4.307
Authors: Christopher J Harvey; Rajesh K Thimmulappa; Sanjay Sethi; Xiaoni Kong; Lonny Yarmus; Robert H Brown; David Feller-Kopman; Robert Wise; Shyam Biswal Journal: Sci Transl Med Date: 2011-04-13 Impact factor: 17.956
Authors: Dino B A Tan; Teck-Hui Teo; Abdul M Setiawan; Nathanael E Ong; Maja Zimmermann; Patricia Price; Lea-Ann S Kirkham; Yuben P Moodley Journal: Immunology Date: 2017-03-20 Impact factor: 7.397
Authors: Gavin C Donaldson; Martin Law; Beverly Kowlessar; Richa Singh; Simon E Brill; James P Allinson; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2015-10-15 Impact factor: 21.405
Authors: R B Gonçalves; R D Coletta; K G Silvério; L Benevides; M Z Casati; J S da Silva; F H Nociti Journal: Inflamm Res Date: 2011-02-05 Impact factor: 4.575
Authors: Richard N van Zyl-Smit; Anke Binder; Richard Meldau; Patricia L Semple; Alicia Evans; Peter Smith; Eric D Bateman; Keertan Dheda Journal: Thorax Date: 2013-11-28 Impact factor: 9.139
Authors: Tariq A Bhat; Suresh Gopi Kalathil; Paul N Bogner; Austin Miller; Paul V Lehmann; Thomas H Thatcher; Richard P Phipps; Patricia J Sime; Yasmin Thanavala Journal: J Immunol Date: 2018-03-19 Impact factor: 5.422
Authors: Michelle Hernandez; Anke Leichtle; Kwang Pak; Joerg Ebmeyer; Sara Euteneuer; Marygorret Obonyo; Donald G Guiney; Nicholas J Webster; David H Broide; Allen F Ryan; Stephen I Wasserman Journal: J Infect Dis Date: 2008-12-15 Impact factor: 5.226